MONTREAL & BOSTON--(BUSINESS WIRE)--Nomic Bio ("Nomic"), the protein profiling company, announced today that it is providing access to the company’s nELISATM platform to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium. The JUMP-CP consortium is coordinated by the Imaging Platform at the Broad Institute of MIT and Harvard and brings together pharma and biotech companies and non-profit partners to create the world’s largest public cell-imaging database to accelerate phenotypic drug discovery. The database, which is scheduled to be publicly available in November 2022, will display the phenotypes of more than one billion cells responding to over 140,000 small molecules and genetic perturbations to enable a systematic mapping of the activity and toxicity of compounds, as well as their associations to relevant disease states. As part of the collaboration, Nomic will provide JUMP-CP scientists and partners the ability to measure 200 secreted proteins in 10,000 samples, which will generate two million protein data points.
“The JUMP-CP consortium is leveraging Cell Painting’s high-content imaging capabilities to create a new data-driven approach to drug discovery,” said Milad Dagher, Ph.D., cofounder and CEO of Nomic. “With Nomic's nELISA platform, we are providing the consortium with a protein profiling technology that is exceptionally accurate, cost-effective and scalable, enabling them to measure thousands of samples and generate millions of protein data points in high throughput. Importantly, the complementary information provided by the two platforms, Cell Painting and nELISA, will enable JUMP-CP scientists to explore more of the biology underlying their compound and genetic screens.”
Nomic’s nELISA platform enables truly scalable and accessible proteomics for high-throughput and high-content protein profiling. nELISA maintains the exquisite sensitivity, specificity, and quantification of traditional ELISAs with the ability to analyze hundreds of proteins in a single assay. The nELISA is supported by innovations in chemistry and software, resulting in a proteomics solution that can plug seamlessly into modern high-throughput biology workflows. By flexibly integrating the consortium's existing assays, Nomic’s nELISA will provide JUMP-CP partners with an orthogonal layer of phenotypic data, associating compounds and genes with secreted protein profiles.
“The JUMP Consortium was founded to investigate the power of information found in cell morphology, through microscopy images. I am very eager to see how information about the secretome profiled using Nomic’s nELISA will complement cell morphology,” said Anne Carpenter, Ph.D., JUMP-CP Principal Investigator and Senior Director of the Imaging Platform at the Broad Institute of Harvard and MIT. “The nELISA easily integrates into Cell Painting workflows because sample prep can happen simultaneously. By broadly profiling cell secretions as well as morphology researchers can get orthogonal information about the cellular response to a genetic or chemical perturbation. Together, I expect these technologies to be very powerful.”
Nomic (formerly nplex biosciences) is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. We are building the nELISA, a next-generation ELISA platform for accurately measuring proteins at scale and at high throughput. The nELISA was designed to seamlessly integrate into current workflows in biology and is uniquely adaptable to a wide variety of use cases within the drug and biomarker development workflows. Nomic is headquartered in Montreal, with labs and offices in Boston. For more information, visit www.nomic.bio.